NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A large cohort study found that among patients admitted with heart failure, the adjusted risk of death in the following 12 months was similar among patients taking atenolol and […]
Category Archives: Cardiovascular disease
NPC Archive Item: Rivaroxaban (Xarelto®▼) reduces symptomatic VTE and death more than enoxaparin in patients undergoing hip or knee replacement
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Results from a pre-specified pooled analysis of the four, double-blind, double-dummy phase 3 (RECORD) studies have been presented as a conference abstract at the 50th Meeting of the American […]
NPC Archive Item: Dual antihypertensive therapy in patients at high risk of CV disease (ACCOMPLISH study)
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The ACCOMPLISH study suggests that in patients at high risk of CV disease, and who require dual antihypertensive therapy to control blood pressure, a combination of an ACE inhibitor […]
NPC Archive Item: Irbesartan ineffective in heart failure with preserved LV ejection fraction
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The I-PRESERVE study found no evidence to support the routine use of an A2RA in patients with heart failure and a preserved left ventricular ejection fraction. Action This data […]
NPC Archive Item: Is lower cholesterol better? – the SEARCH continues
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Early results of the SEARCH study have been presented at the American Heart Association conference and as such have not yet been fully evaluated. They suggest no statistically significant […]
NPC Archive Item: Higher dose rosuvastatin in lower risk patients – the JUPITER study
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. In the JUPITER study, rosuvastatin 20mg daily reduced the risk of major CV events compared with placebo in people with few elevated CV risk factors apart from a raised […]
NPC Archive Item: Cheaper generic statins are just as successful at achieving QOF targets
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Petty D, Lloyd D. Can cheap generic statins achieve national cholesterol lowering targets? J Health Serv Res Policy 2008;13:99–102 Primary Care Trusts (PCTs) with a high proportion of simvastatin […]
NPC Archive Item: Aspirin ineffective for primary prevention in patients with diabetes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in […]
NPC Archive Item: SEAS and ezetimibe▼: no benefits on CV endpoints, questions raised over cancer risk
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Rossebø AB, et al for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359 (early online publication, September 2nd […]
NPC Archive Item: Omega-3 polyunsaturated fatty acids, but not rosuvastatin, may provide a benefit in heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (early online publication) 31 August 2008; […]